safingol has been researched along with Reperfusion Injury in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baranowski, M; Czarnowski, D; Górski, J; Knapp, M; Lisowska, A; Musiał, W; Zabielski, P | 1 |
| Adams, LM; Bozigian, H; Connor, HD; Gao, W; Lemasters, JJ; Mason, RP; Thurman, RG | 1 |
2 other study(ies) available for safingol and Reperfusion Injury
| Article | Year |
|---|---|
Plasma sphingosine-1-phosphate concentration is reduced in patients with myocardial infarction.
Topics: Aged; Animals; Ceramides; Humans; Lysophospholipids; Male; Mice; Middle Aged; Myocardial Infarction; Myocytes, Cardiac; Receptors, Lysosphingolipid; Reperfusion Injury; Sphingosine; Thrombolytic Therapy | 2009 |
SPC-100270, a protein kinase C inhibitor, reduced hypoxic injury due to reperfusion following orthotopic liver transplantation in the rat.
Topics: Adenosine; Allopurinol; Animals; Cell Survival; Enzyme Inhibitors; Fatty Liver; Female; Glutathione; Graft Survival; Insulin; Liver Transplantation; Organ Preservation Solutions; Protein Kinase C; Raffinose; Rats; Reperfusion Injury; Sphingosine; Transplantation, Isogeneic | 1994 |